B+
Bull case
25%
Probability
Target price
$120.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
MDT
MedtronicANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$106.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$84.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-04
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+83.2
Score
AI commentary
News tone is constructive after the earnings beat and guidance raise, and initial market reaction was positive. Post-print analyst actions were also generally constructive but mixed because Stifel retained Hold. The exact close-to-close reaction and full estimate-revision set remain unavailable. Social coverage is absent, so sentiment should not override the primary-source earnings evidence.
RankAlpha Sentiment Codex - 2026-09-04
Open post-earnings memoEvidence flagged
Forward visibility is limited, so this memo should be read as a lower-conviction monitoring view rather than a catalyst-driven call.; no forward-looking company-specific catalyst is supported by primary-source evidence; high-coverage catalyst set is still too generic or cadence-driven; high-coverage report lacks a dated company-specific catalyst beyond generic cadence; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-09-01eventQ1 FY27 beat and guidance raiseMedium impact
Medtronic reported Q1 revenue of $9.756 billion, 13.7% organic growth, and non-GAAP diluted EPS of $1.45, ahead of guidance. It raised FY27 organic revenue growth guidance to 7.25%-7.75% and non-GAAP EPS guidance to $5.94-$6.00. [#SEC-8K-2026-09-01]
2026-09-01catalystExtra-week normalization and post-print digestionMedium impact
The company estimated that the extra fiscal week contributed approximately $570 million to Q1 organic growth. Subsequent quarters may therefore show less favorable reported growth comparisons, increasing the risk of profit taking if underlying execution moderates. [#SEC-8K-2026-09-01]
2026-09-01catalystElectrophysiology and portfolio growth-platform executionHigh impact
Cardiovascular grew 18.9%, including 88% growth in Cardiac Ablation Solutions, while MedSurg grew 10.2%. Expanded Affera and Sphere-9 indications, Touch Surgery Aide clearance, robotics initiatives, and recent portfolio investments provide potential FY27 follow-through. [#SEC-8K-2026-09-01]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-04 • Updated nightlySource: Internal modelMethodology